focus -WSS

focus

author：leisure time 2025-09-06 03:52:57 - browse：4358

A glass office building of MassMutual with its sign on the top left — insurance coverage from STAT — Adobe

One of the country’s biggest life insurers is venturing into genetic testing, an area that’s historically been a minefield for that industry, in a purported effort to keep its members alive longer.

MassMutual announced Tuesday that it’s offering many of its 4.2 million policyholders free genetic risk assessments for eight common diseases, like heart disease, type 2 diabetes, and breast cancer. The Springfield, Mass.-based insurer hopes that when people learn they carry a genetic predisposition, they’ll take action to lower their risk through diet, exercise, and getting regular screenings.

Viewed one way, it’s a win-win: The longer its members live, the longer MassMutual can collect and invest their premiums without paying out.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Brain technologies pose threats that are all too real, experts warn

WSS

The surgeon had a dilemma only a Nazi medical text could resolve

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Test for long Covid? Researchers find new clue in blood samples

Think you might have Covid

Biotech venture capitalists face new demands from investors

Test for long Covid? Researchers find new clue in blood samples

knowledge

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

Biotech venture capitalists face new demands from investors

As demand for Covid shots wanes, Moderna seeks its next success

AI for drug discovery: Experts on separating hype from reality

Novavax promises a turnaround & Lilly roils the obesity market

Sepsis can kill a child within hours. Here's how hospitals are fighting back

George Santos makes 1st court appearance after pleading not guilty to 13 counts

How digital therapeutics firms are pivoting after Pear's bankruptcy

Jerome Adams on the need for new antivirals for Covid

Most antidepressants don't work on kids, teens, study finds

focus

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Black vets could get higher VA benefits if race not used in lung test

Francis Collins on trust in science and how Covid communications failed

AltruBio raises $225 million to develop ulcerative colitis drug

Welsh Carson private equity firm escapes from FTC antitrust case

Black vets could get higher VA benefits if race not used in lung test

entertainment

focus

focus

focus